NEW BRUNSWICK, N.J., November 17, 2025 — Johnson & Johnson (NYSE: JNJ) said today that it has reached a final deal to pay $3.05 billion in cash to acquire Halda Therapeutics, which will greatly increase its capacity to treat cancer.
With the acquisition, Johnson & Johnson will own Halda’s exclusive RIPTACTM (Regulated Induced Proximity Targeting Chimaera) platform. A new class of targeted oral therapies that can specifically destroy cancer cells, including ones that have grown resistant to conventional treatments, will be made possible by this technology.
The deal’s focal point is Halda’s primary asset, HLD-0915, a once-daily, clinical-stage treatment for prostate cancer. The press release claims that HLD-0915’s ongoing Phase 1/2 clinical trial has demonstrated “impressive preliminary efficacy and a strong early safety profile.” Prostate cancer, which is expected to claim 1.7 million new patients worldwide by 2030, has common treatment-resistance mechanisms that the therapy’s unique mechanism is designed to overcome.
In addition to its lead candidate, Halda’s platform has the potential to develop therapies outside of oncology and a pipeline of earlier-stage treatments for other solid tumours, such as lung and breast cancers.
Read More: Merck to Acquire Cidara Therapeutics for $9.2 Billion, Gaining Late-Stage Antiviral Agent CD388
The acquisition was presented as a significant strategic move by Jennifer Taubert, Executive Vice President and Worldwide Chairman of Innovative Medicine at Johnson & Johnson. Taubert said, “This acquisition further strengthens our deep oncology pipeline with an exciting lead asset in prostate cancer and a platform capable of treating multiple cancers and diseases beyond oncology, providing a potential mid- and long-term catalyst for growth.”
Johnson & Johnson intends to expedite the development of Halda’s assets by utilising its extensive global R&D, commercial, and manufacturing capabilities.
Halda’s innovative technology is designed to work even when cancers no longer respond to standard treatments using a novel mechanism that enables the selective killing of cancer cells,
We are eager to accelerate the ongoing Phase 1/2 clinical trial of HLD-0915 and progress a pipeline of novel product candidates based on RIPTAC™ technology.
John C. Reed
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
The transaction, which will be accounted for as a business combination, is expected to close within the next few months, pending antitrust clearance and other customary closing conditions. Johnson & Johnson noted the deal is expected to cause a $0.15 dilution to its adjusted earnings per share in 2026, citing short-term financing and non-recurring charges.
Last Modified:
